StockData

RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3076% below fair value
$4.83−0.47 (-8.87%)

Close on Nov 17, 2026Market cap $200.90MP/E –Yield –

RxSight operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

RxSight's operating income for the twelve months ending Jun 30, 2026 was -$55.11M. For fiscal 2025 it was -$48.19M. The highest annual figure on record is -$35.41M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$48.19M–
FY2024Dec 31, 2024-$36.86M–
FY2023Dec 31, 2023-$50.09M–
FY2022Dec 31, 2022-$63.32M–
FY2021Dec 31, 2021-$52.79M–
FY2020Dec 31, 2020-$35.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$13.77M–
Q1 FY2026Mar 31, 2026-$17.83M–
Q4 FY2025Dec 31, 2025-$11.34M–
Q3 FY2025Sep 30, 2025-$12.18M–
Q2 FY2025Jun 30, 2025-$14.00M–
Q1 FY2025Mar 31, 2025-$10.67M–
Q4 FY2024Dec 31, 2024-$8.63M–
Q3 FY2024Sep 30, 2024-$9.23M–
Q2 FY2024Jun 30, 2024-$8.33M–
Q1 FY2024Mar 31, 2024-$10.67M–
Q4 FY2023Dec 31, 2023-$10.85M–
Q3 FY2023Sep 30, 2023-$12.51M–
Q2 FY2023Jun 30, 2023-$13.63M–
Q1 FY2023Mar 31, 2023-$13.10M–
Q4 FY2022Dec 31, 2022-$14.99M–
Q3 FY2022Sep 30, 2022-$15.96M–
Q2 FY2022Jun 30, 2022-$15.79M–
Q1 FY2022Mar 31, 2022-$16.58M–
Q4 FY2021Dec 31, 2021-$14.66M–
Q3 FY2021Sep 30, 2021-$13.11M–
Q2 FY2021Jun 30, 2021-$13.88M–
Q1 FY2021Mar 31, 2021-$11.14M–
Q4 FY2020Dec 31, 2020-$8.30M–
Q3 FY2020Sep 30, 2020-$8.91M–
Q2 FY2020Jun 30, 2020-$8.81M–

More RxSight figures

See a number that looks wrong?